[go: up one dir, main page]

MX2019003938A - Compuestos espirociclicos. - Google Patents

Compuestos espirociclicos.

Info

Publication number
MX2019003938A
MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A
Authority
MX
Mexico
Prior art keywords
spirocyclic compounds
compounds
spirocyclic
ameliorating
treating
Prior art date
Application number
MX2019003938A
Other languages
English (en)
Inventor
Kahraman Mehmet
Qinhua Huang Peter
Duane Bunker Kevin
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of MX2019003938A publication Critical patent/MX2019003938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se describen compuestos espirocíclicos, junto con composiciones farmacéuticas y métodos para mejorar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2019003938A 2016-10-05 2017-10-03 Compuestos espirociclicos. MX2019003938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
MX2019003938A true MX2019003938A (es) 2019-06-10

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003938A MX2019003938A (es) 2016-10-05 2017-10-03 Compuestos espirociclicos.

Country Status (13)

Country Link
US (2) US10934304B2 (es)
EP (1) EP3523306A4 (es)
JP (2) JP6949952B2 (es)
KR (1) KR20190075931A (es)
CN (1) CN109890827A (es)
AU (1) AU2017339890A1 (es)
BR (1) BR112019005305A2 (es)
CA (1) CA3037064A1 (es)
IL (1) IL265752A (es)
MX (1) MX2019003938A (es)
RU (1) RU2019107667A (es)
TW (1) TW201817732A (es)
WO (1) WO2018067512A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
DK3846904T3 (da) * 2018-09-07 2023-08-21 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) * 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
TW202535881A (zh) * 2023-10-31 2025-09-16 美商Ｃ４醫藥公司 用於降解突變braf之化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305776B1 (en) * 2004-05-14 2019-09-25 Vertex Pharmaceuticals Incorporated Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds
CA2633023C (en) * 2005-12-13 2015-11-24 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
EP2170893A1 (en) * 2007-06-18 2010-04-07 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP2509636B1 (en) 2009-12-07 2017-07-19 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) * 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
AR095036A1 (es) 2013-03-14 2015-09-16 Kalyra Pharmaceuticals Inc Compuestos analgésicos bicíclicos
EP3237420B1 (en) 2014-12-22 2018-09-26 Eli Lilly and Company Erk inhibitors
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds

Also Published As

Publication number Publication date
EP3523306A1 (en) 2019-08-14
CN109890827A (zh) 2019-06-14
BR112019005305A2 (pt) 2019-07-02
KR20190075931A (ko) 2019-07-01
NZ751398A (en) 2021-03-26
AU2017339890A1 (en) 2019-04-11
RU2019107667A (ru) 2020-11-06
TW201817732A (zh) 2018-05-16
US20210115058A1 (en) 2021-04-22
WO2018067512A8 (en) 2018-11-01
US20200207776A1 (en) 2020-07-02
JP2019534261A (ja) 2019-11-28
CA3037064A1 (en) 2018-04-12
RU2019107667A3 (es) 2021-01-27
EP3523306A4 (en) 2020-05-06
WO2018067512A1 (en) 2018-04-12
IL265752A (en) 2019-06-30
JP6949952B2 (ja) 2021-10-13
US10934304B2 (en) 2021-03-02
JP2021193138A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2019003938A (es) Compuestos espirociclicos.
ZA201807399B (en) Egfr inhibitor compounds
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX379622B (es) Compuestos espirociclicos
MX2018003472A (es) Moduladores de la expresion de kras.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MY187540A (en) Compounds active towards bromodomains
MX2019007021A (es) Anticuerpos il-11ra.
GB2541571A (en) Pharmaceutical compositions
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2017014436A (es) Compuestos biciclicos.
MX2021009899A (es) Administracion y dosificacion de diaminofenotiazinas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
EP4286005A3 (en) Cancer treatment
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2016130581A8 (en) Combination cancer therapy
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.